BERLIN / MUNICH – 25 November 2019 – Inceptua Group (formerly Multipharma GmbH), a global pharmaceutical company and service provider, and Bendalis GmbH, a German manufacturer of generic oncology products and special therapeutics, today announced the signing of an exclusive agreement for the supply of clinical trial material for generic oncology products.
Through this agreement, Inceptua will become the exclusive distributor of Bendalis' products for worldwide use in clinical trials, thereby offering clinical trial sponsors rapid access to Brexit-compliant oncology standard of care medicines manufactured within the European Union.
„With this agreement, Bendalis and Inceptua are joining forces to ensure our clients have optimal sourcing and supply of medicines for use in oncology clinical trials. Together, we pursue the goal of providing patients with uninterrupted access to high-quality products through a secure and stable supply chain.“ So Alan Raffensperger, CEO of the Inceptua Group.
„In oncology, we are seeing a growing need and increased demand for products. We see Inceptua as an ideal partner for sales and optimising the provision of clinical trial material for customers. The constant and reliable delivery of products is a crucial component in clinical trials, and together we can offer a flexible yet dependable solution that helps customers minimise extra effort and reduce costs.“ So Christian Parvany, CEO of Bendalis.
With over 8,000 cancer studies currently underway worldwide, the need for significant quantities of essential medicines is clear. Through this agreement, Inceptua will expand its existing broad portfolio of oncology comparator drugs and standard-of-care medicines for use in clinical trials with exclusive access to Bendalis' product portfolio, which is commonly used in chemotherapy. The products include Carboplatin, Docetaxel, Gemcitabine, Paclitaxel, Oxaliplatin, Vinorelbine, Irinotecan, and Fluorouracil (5FU).
All enquiries are gladly accepted via bendalis@inceptua.com.
Further information is available from:
Bendalis GmbH
Stefan Eichmeier
Head of Global Sales
stefan.eichmeier@bendalis.com
+49 89 450808780
Inceptua Group
Bodil Jonason
Head of Communications
bodil.jonason@inceptua.com
+46 733 745031
About Inceptua Group and Bendalis:
The Bendalis Ltd
Bendalis is a leading speciality pharmaceutical company focused on developing and promoting generic oncology products and its own niche oncology products within Germany and in various international markets.
The existing know-how across the entire portfolio offers the advantage that every customer receives a very specific, comprehensive service with regard to market approval, production, and sales strategies.
Through collaboration with doctors, pharmacists, wholesalers, and partners worldwide, Bendalis possesses a distribution network and access to comprehensive information on markets and products.
Inceptua
As a pharmaceutical company and service partner, Inceptua covers the entire product lifecycle: from the provision of comparator products for clinical trials and „early access“ programmes to licensing and marketing of products.
We are partners with life science companies of all sizes and boast over 20 years of industry experience. Our offering in the pharmaceutical and biotech sectors includes product registration and commercialisation through licensing and flexible partnerships. We have extensive experience in strategy implementation and the operational execution of programmes for access to unlicensed medicines, so that patients can receive pharmaceutical products that are still in clinical development. Inceptua's Clinical Trials Services division also offers the supply and manufacturing of high-quality clinical comparator products with an agile global supply chain that ensures on-demand product delivery.
Inceptua operates worldwide with offices across Europe, the USA and Asia.